Investment Thesis
IRIX demonstrates early revenue growth (+8.2% YoY) and improving loss trends, but the core business remains operationally unprofitable with -2.7% operating margin and critically, negative free cash flow of -$1.4M, creating unsustainable burn relative to $4.6M cash reserves. Without reaching operating profitability and positive cash generation within 2-3 quarters, the company faces potential liquidity constraints despite currently adequate short-term ratios.
Strengths
- Revenue growing 8.2% YoY in medtech sector with 40.2% gross margins showing product demand
- Strong liquidity position with 1.92x current ratio and 4.6M cash reserves provides near-term runway
- Improving loss trajectory with net income improving 50.2% YoY suggests operational corrections underway
Risks
- Negative operating cash flow of -1.3M quarterly with -1.4M free cash flow is unsustainable and indicates business model not yet viable at current scale
- Operating losses persist at -2.7% margin with -11.1% ROE showing value destruction on shareholder capital
- Small revenue base of $11.8M and current burn rate implies only 3-4 quarters of cash runway before potential capital need if trends don't reverse
Key Metrics to Watch
- Operating cash flow trajectory - must turn positive within next 2-3 quarters to validate viability
- Path to operating profitability - critical that operating margin improves beyond current -2.7%
- Gross margin sustainability - monitor if 40.2% margins hold as business scales and validates unit economics
Financial Metrics
Revenue
11.8M
Net Income
-524.0K
EPS (Diluted)
$-0.03
Free Cash Flow
-1.4M
Total Assets
28.3M
Cash
4.6M
Profitability Ratios
Gross Margin
40.2%
Operating Margin
-2.7%
Net Margin
-4.4%
ROE
-11.1%
ROA
-1.9%
FCF Margin
-12.2%
Balance Sheet & Liquidity
Current Ratio
1.92x
Quick Ratio
1.19x
Debt/Equity
0.21x
Debt/Assets
83.3%
Interest Coverage
-5.59x
Long-term Debt
1.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-20T07:14:42.787670 |
Data as of: 2026-04-04 |
Powered by Claude AI